Applied Biosystems and SAIC-Frederick collaborate to validate biomarkers for cancer research

19-May-2006

Applied Biosystems, an Applera Corporation business, announced that it has entered into a collaboration with the Core genotyping Facility, SAIC-Frederick, Inc., a contractor for the National Cancer Institute (NCI), on a series of biomarker studies for cancer research. The NCI-funded Core Genotyping Facility will use Applied Biosystems' entire TaqMan® Drug metabolism Genotyping Assay collection to examine genetic variations in the HapMap and SNP500Cancer samples in order to validate additional cancer biomarkers.

In support of the NCI, the Core Genotyping Facility is using more than 2,400 TaqMan Drug Metabolism Genotyping Assays to generate the genotypes for samples from the International HapMap Project and from NCI's SNP500Cancer standard sample panel. In addition, select assays with significant correlation from data analysis will be used to genotype individuals who participated in a pharmacogenetic study at the NCI evaluating treatment for Non-Hodgkin lymphoma.

"The objective of this study is to better understand the genetic differences associated with individual responses to cancer treatment," said Dennis A. Gilbert, Ph.D., Chief Scientific Officer for Applied Biosystems.

The Core Genotyping Facility will use samples from the HapMap project SNP500Cancer and Human Diversity Panel as controls to evaluate the genes included in the TaqMan Drug Metabolism Genotyping Assays. Applied Biosystems and the Core Genotyping Facility will jointly analyse the resulting genotype data, and compare resulting data with previously published genotype and/or sequencing data for the same variants and individuals.

https://www.bionity.com/en/news/54889/applied-biosystems-and-saic-frederick-collaborate-to-validate-biomarkers-for-cancer-research.html